Drug intelligence / Profile preview

trapidil

Development stage: Unknown
Lead developer: PLIVA
Modality: Small Molecules
Administration: Oral

Overview

Trapidil is a small molecule vasodilator and antiplatelet drug primarily used in the treatment of chronic stable angina and coronary heart disease. It acts as an antagonist of platelet-derived growth factor (PDGF), inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase enzymes, and suppresses platelet aggregation. The increase in cAMP potentiates inhibition of platelets by adenosine, reduces thromboxane A2 generation, and leads to vasodilation. Trapidil also exhibits antiproliferative effects by reducing mitogenesis due to PDGF binding to its receptor, which may help prevent restenosis after angioplasty[1][2][3][5][6].

Brand names: TRAPIDIL Tablets 100mg "SAWAI"
Other names: triazolopyrimidine

Targets

PDE (Phosphodiesterase family)PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on trapidil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trapidil.

Explore the full profile